Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiff Oncology, Inc. filings document regulatory disclosures for a clinical-stage oncology company developing onvansertib and PLK1-inhibition programs. Recent Form 8-K reports cover financial results, business updates, Regulation FD presentation materials, CRDF-004 clinical disclosures in first-line RAS-mutated metastatic colorectal cancer and other material events tied to the company's development strategy.
The company's proxy and current reports also address board and executive governance, officer appointments and departures, separation agreements, compensation arrangements, equity awards and Nasdaq inducement grants. These filings include formal disclosure of risk themes common to clinical-stage biotechnology issuers, including clinical-trial uncertainty, financing needs, dependence on key personnel and operating disruptions.
Cardiff Oncology, Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026. A quorum of 41,614,848 common shares was represented in person or by proxy.
Stockholders elected six directors to serve until the 2027 Annual Meeting, including Dr. James O. Armitage, Dr. Rodney Markin, Mani Mohindru, Ph.D., Gary W. Pace, Ph.D., Renee P. Tannenbaum, Pharm.D., and Lâle White. Each nominee received approximately 18.7–18.9 million votes in favor and no votes against, with broker non-votes around 22.3 million.
Stockholders also ratified BDO USA, P.C. as independent registered public accounting firm for the fiscal year ended December 31, 2026, with 40,239,508 votes for and 1,070,807 against. An amendment to the 2021 Equity Incentive Plan to increase the number of shares issuable to 15,150,000 was approved with 10,740,460 votes for and 8,063,520 against. In a non-binding advisory vote, compensation of the named executive officers was approved with 17,120,176 votes for and 1,772,185 against.
Cardiff Oncology, Inc. shared updated Phase 2 CRDF-004 data for its PLK1 inhibitor onvansertib in first-line RAS-mutated metastatic colorectal cancer and outlined plans for a registrational Phase 3 trial. The 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a 72% objective response rate, about 30% higher than standard FOLFIRI/bevacizumab. Median progression-free survival has not yet been reached in key onvansertib arms, while standard-of-care FOLFIRI/bevacizumab showed a median PFS of 12.22 months by investigator assessment. The company completed a successful End-of-Phase 2 FDA meeting and is proposing a ~640-patient pivotal trial with dual primary endpoints of objective response rate and progression-free survival, designed to allow accelerated approval based on response and full approval based on PFS. Safety data indicate no unexpected or new toxicities when onvansertib is added to existing chemotherapy and bevacizumab regimens.
Cardiff Oncology reported first quarter 2026 results and a major clinical and leadership update. The company posted a net loss attributable to common stockholders of $12.4 million, or $0.18 per share, compared with a loss of $13.4 million, or $0.20 per share, a year earlier. Total operating expenses fell to $12.9 million from $14.5 million as research and development spending declined, partly offset by higher selling, general and administrative costs tied to severance and stock‑based compensation. Cash, cash equivalents and short‑term investments totaled $46.1 million as of March 31, 2026, and the company expects this to fund operations into the first quarter of 2027.
Clinically, Cardiff highlighted positive randomized Phase 2 CRDF‑004 data in first‑line RAS‑mutated metastatic colorectal cancer, where the 30 mg onvansertib plus FOLFIRI/bevacizumab arm achieved a confirmed objective response rate of 72.2% versus 43.2% across combined standard‑of‑care arms and showed improved progression‑free survival (hazard ratios 0.38 and 0.37, p<0.05) without significant added toxicity. Following a successful End‑of‑Phase 2 FDA meeting, the company selected a 30 mg onvansertib dose with FOLFIRI/bev for a planned Phase 3 registrational trial and plans to share more details by mid‑2026. Cardiff also announced that updated CRDF‑004 data will be presented in a rapid oral session at the 2026 ASCO Annual Meeting and that new preclinical data support combining onvansertib with an antibody‑drug conjugate in HER2‑low breast cancer models. Leadership was strengthened with Mani Mohindru appointed permanent CEO and new CFO and COO hires to support upcoming clinical and regulatory milestones.
Cardiff Oncology reported a net loss of $12.3 million for the quarter ended March 31, 2026, on royalty revenue of just $41,000. Operating expenses were $12.9 million, with research and development down to $6.8 million and selling, general and administrative expenses up to $6.1 million, largely from severance and stock-based compensation.
The company ended the quarter with $46.1 million in cash, cash equivalents and short‑term investments and used $12.3 million in operating cash, and management concluded there is substantial doubt about its ability to continue as a going concern beyond the next 12 months without new financing. Cardiff advanced its lead PLK1 inhibitor onvansertib, highlighting strong Phase 2 data in first‑line RAS‑mutated metastatic colorectal cancer and alignment with the FDA on a Phase 3 design, but also disclosed a license dispute with Nerviano that could, if unresolved, lead to termination of the onvansertib license and materially harm the business.
Cardiff Oncology Chief Operating Officer Ajay Aggarwal received a grant of stock options covering 400,000 shares of common stock. The options have an exercise price of $1.72 per share and expire on April 27, 2036, giving him a long-term incentive tied to the company’s share price.
According to the vesting schedule, 100,000 options vest on April 27, 2027, and 8,333 options vest monthly for 36 months beginning on May 27, 2027. After this grant, Aggarwal holds 400,000 stock options directly under this award.
Cardiff Oncology, Inc. Chief Operating Officer Ajay Aggarwal has filed an initial statement of beneficial ownership on Form 3. The filing reports no buy, sell, or other equity transactions and shows no derivative positions, serving as a baseline disclosure of his insider status.
Cardiff Oncology is asking stockholders to vote at its June 11, 2026 annual meeting on four main items: electing six directors, ratifying BDO USA as auditor, expanding the 2021 Omnibus Equity Incentive Plan, and approving executive pay on an advisory basis.
The equity plan share reserve would increase by 3,000,000 shares, bringing total issuable shares to 15,150,000, compared with 68,369,896 common shares outstanding as of April 20, 2026. The company highlights recent equity burn and overhang levels and positions the request as competitive within life sciences peers.